Revelation Biosciences (REVB) Other Accumulated Expenses (2021)
Revelation Biosciences (REVB) posted quarterly Other Accumulated Expenses of $1.5 million for Q4 2021, up 19.72% quarter-over-quarter from $1.3 million in Q3 2021.
Revelation Biosciences (REVB) Other Accumulated Expenses (2021) Analysis & Trends
Revelation Biosciences (REVB) has reported Other Accumulated Expenses for 1 consecutive years, with $1.5 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Other Accumulated Expenses changed N/A year-over-year to $1.5 million; the TTM figure through Dec 2021 stood at $1.5 million (changed N/A YoY), while the FY2021 annual figure was $1.5 million, changed N/A from the prior year.
- Other Accumulated Expenses advanced to $1.5 million in Q4 2021 per REVB's latest filing, from $1.3 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.5 million in Q4 2021 and bottomed at $140459.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.54 Mn |
| Sep 30, 2021 | 1.28 Mn |
| Jun 30, 2021 | 140,459.00 |